HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMMUNEONCO-B

6.440

+0.0500.78%

Volume:1.04M

Turnover:6.68M

Market Cap:2.62B

PE:-7.16

High:6.520

Open:6.360

Low:6.270

Close:6.390

Loading ...

Overview Company News Filings

ImmuneOnco Biopharmaceuticals Gets $5 Million Payout Under License Deal

MT Newswires Live

ImmuneOnco Biopharmaceuticals Names Chief Business Officer

MT Newswires Live

ImmuneOnco Biopharmaceuticals Gets Go-Ahead to List Converted H Shares in Hong Kong

MT Newswires Live

HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%

Tiger Newspress

BRIEF-Immuneonco Biopharmaceuticals Shanghai Says NMPA Accepted Application For Clinical Trial Of Imc-003/Imm72

ImmuneOnco Biopharmaceuticals Shanghai Inc - Nmpa Accepted Application for Clinical Trial of Imc-003/Imm72

THOMSON REUTERS

BRIEF-Immuneonco Biopharmaceuticals Shanghai Says CEO Purchased 150,000 H Shares Of Co

ImmuneOnco Biopharmaceuticals Shanghai Inc - CEO Purchased a Total of 150,000 H Shares of Co at an Average Price of HK$5.278 per Share

THOMSON REUTERS

Stock Track | ImmuneOnco Soars 5.17% Following Annual Revenue Announcement of RMB74.1 Million

BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Revenue Was RMB74.1 Million For Year

ImmuneOnco Biopharmaceuticals Shanghai Inc - Revenue Was RMB74.1 Mln for Year

THOMSON REUTERS

ImmuneOnco Biopharmaceuticals (Shanghai)'s Cancer Drug Gets NMPA`s Nod for Clinical Trial

MT Newswires Live

BRIEF-Immuneonco Biopharmaceuticals Shanghai Gets Approval For Clinical Trial Of IMM01 (Timdarpacept)

ImmuneOnco Biopharmaceuticals Shanghai - Approval From Nmpa China for Clinical Trial of Imm01 (Timdarpacept)

THOMSON REUTERS

ImmuneOnco Biopharmaceuticals Completes Disposal of Subsidiary; Shares Plunge 15%

MT Newswires Live

Instil Bio Inc - Plans U.S. Trial of Syn-2510/Imm2510 in 2H 2025

THOMSON REUTERS

Instil Bio Inc - Initial Clinical Data From 1L Advanced Nsclc Trial in China Expected 2H 2025

THOMSON REUTERS

Instil Bio Announces Clinical Progress in China for Imm2510/Syn-2510, a Clinical-Stage Pd-L1xvegf Bispecific Antibody

THOMSON REUTERS

Institutions along with retail investors who hold considerable shares inImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) come under pressure; lose 11% of holdings value

Simply Wall St.

ImmuneOnco Biopharmaceuticals' Phase Ib/II Cancer Drug Clinical Study Administers Dose on First Patient

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/01541/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01541","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"IMMUNEONCO-B","latestPrice":6.44,"timestamp":1746778087014,"preClose":6.39,"halted":0,"volume":1040400,"delay":0,"floatShares":382000000,"shares":407000000,"eps":-0.8997257384310218,"marketStatus":"Market Closed","change":0.05,"latestTime":"05-09 16:08:07","open":6.36,"high":6.52,"low":6.27,"amount":6683087,"amplitude":0.039124,"askPrice":6.44,"askSize":11000,"bidPrice":6.38,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.8997257384310218,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":7,"adr":0,"listingDate":1693843200000,"exchange":"SEHK","adjPreClose":6.39,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"volumeRatio":0.5488499683709158,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01541\",,,,,undefined,":{"symbol":"01541","floatShares":382000000,"roa":"-21.43%","roe":"-44.38%","lyrEps":-0.899726,"volumeRatio":0.5488499683709158,"shares":407000000,"dividePrice":0,"high":6.52,"amplitude":0.039124,"preClose":6.39,"low":6.27,"week52Low":3.21,"pbRate":"3.59","psRate":"30.67","week52High":22,"institutionHeld":0,"latestPrice":6.44,"committee":-0.964286,"eps":-0.8997257384310218,"divideRate":0,"volume":1040400,"delay":0,"ttmEps":-0.8997257384310218,"open":6.36,"prevYearClose":5.16,"prevWeekClose":6.37,"prevMonthClose":6.25,"prevQuarterClose":5.84,"fiveDayClose":6.25,"twentyDayClose":4.91,"sixtyDayClose":5.45},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01541\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533993113","title":"ImmuneOnco Biopharmaceuticals Gets $5 Million Payout Under License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2533993113","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533993113?lang=en_us&edition=fundamental","pubTime":"2025-05-07 21:53","pubTimestamp":1746626007,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   has received a second near-term payment of $5 million from Axion Bio, previously known as SynBioTx, a Wednesday Hong Kong bourse filing said.The company had, in August 2024, granted Axion Bio an exclusive license for the research, development, and commercialization of the anti-tumor drugs outside of Mainland China, Hong Kong, Macau, and Taiwan.As of Wednesday, the pharmaceutical firm has received a total of $20 million in upfront and near-term payments under the license contract.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2533479645","title":"ImmuneOnco Biopharmaceuticals Names Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2533479645","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533479645?lang=en_us&edition=fundamental","pubTime":"2025-05-06 14:01","pubTimestamp":1746511308,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   named Weihai He as chief business officer effective Monday, a Tuesday Hong Kong bourse filing said.From 2021 to 2025, He served on the board of supervisors of the Global Health Drug Discovery Institute and a deputy director of business development and licensing at Bill and Melinda Gates Foundation.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2530017279","title":"ImmuneOnco Biopharmaceuticals Gets Go-Ahead to List Converted H Shares in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2530017279","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530017279?lang=en_us&edition=fundamental","pubTime":"2025-04-25 17:54","pubTimestamp":1745574858,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   has received approval from the Hong Kong bourse for the listing of 14,114,006 converted H shares, a Thursday filing with the Hong Kong bourse said.Following the conversion and listing, the biopharmaceutical firm's H shares will rise to 97.29% from 93.83% of its total shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"1104696869","title":"HK Movers | Biotech Stocks Jump With ImmuneOnco up 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1104696869","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104696869?lang=en_us&edition=fundamental","pubTime":"2025-04-24 09:49","pubTimestamp":1745459345,"startTime":"0","endTime":"0","summary":"Biotech stocks surged in Hong Kong, with ImmuneOnco up 10%, RemeGen up 9%, Akeso and QYUNS up 6%, Lepu Biopharma up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","02509","09926","09995","02157"],"gpt_icon":0},{"id":"2524541851","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says NMPA Accepted Application For Clinical Trial Of Imc-003/Imm72","url":"https://stock-news.laohu8.com/highlight/detail?id=2524541851","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524541851?lang=en_us&edition=fundamental","pubTime":"2025-04-02 23:20","pubTimestamp":1743607215,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says NMPA Accepted Application For Clinical Trial Of Imc-003/Imm72April 2  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:NMPA ACCEPTED APPLICATION FOR CLINICAL TRIAL OF IMC-003/IMM72Further company coverage: 1541.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2524542494","title":"ImmuneOnco Biopharmaceuticals Shanghai Inc -  Nmpa Accepted Application for Clinical Trial of Imc-003/Imm72","url":"https://stock-news.laohu8.com/highlight/detail?id=2524542494","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524542494?lang=en_us&edition=fundamental","pubTime":"2025-04-02 22:02","pubTimestamp":1743602537,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0DM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2522868383","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says CEO Purchased 150,000 H Shares Of Co","url":"https://stock-news.laohu8.com/highlight/detail?id=2522868383","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522868383?lang=en_us&edition=fundamental","pubTime":"2025-03-26 23:02","pubTimestamp":1743001322,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says CEO Purchased 150,000 H Shares Of CoMarch 26  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:CEO PURCHASED A TOTAL OF 150,000 H SHARES OF CO AT AN AVERAGE PRICE OF HK$5.278 PER SHAREFurther company coverage: 1541.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2522009718","title":"ImmuneOnco Biopharmaceuticals Shanghai Inc -  CEO Purchased a Total of 150,000 H Shares of Co at an Average Price of HK$5.278 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2522009718","media":"THOMSON REUTERS","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522009718?lang=en_us&edition=fundamental","pubTime":"2025-03-26 22:20","pubTimestamp":1742998849,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90W3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"ImmuneOnco Biopharmaceuticals Shanghai Inc -  CEO Purchased a Total of 150,000 H Shares of Co at an Average Price of HK$5.278 per Share","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1192398607","title":"Stock Track | ImmuneOnco Soars 5.17% Following Annual Revenue Announcement of RMB74.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1192398607","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192398607?lang=en_us&edition=fundamental","pubTime":"2025-03-26 09:46","pubTimestamp":1742953611,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals Shanghai Inc  saw its stock price surge by 5.17% during intraday trading on Wednesday, following the release of its annual financial results. The company, which specializes in biopharmaceuticals, announced its yearly revenue figures late Tuesday evening, sparking investor interest.According to the financial report, ImmuneOnco recorded an annual revenue of RMB74.1 million. However, the company also reported a loss attributable of RMB315.9 million for the year. Despit","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | ImmuneOnco Soars 5.17% Following Annual Revenue Announcement of RMB74.1 Million","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["01541"],"gpt_icon":0},{"id":"2522009876","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Revenue Was RMB74.1 Million For Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2522009876","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522009876?lang=en_us&edition=fundamental","pubTime":"2025-03-25 23:17","pubTimestamp":1742915832,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Says Revenue Was RMB74.1 Million For YearMarch 25  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:REVENUE WAS RMB74.1 MILLION FOR YEARFY LOSS ATTRIBUTABLE RMB315.9 MILLIONFurther company coverage: 1541.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"gpt_icon":0},{"id":"2522005445","title":"ImmuneOnco Biopharmaceuticals Shanghai Inc - Revenue Was RMB74.1 Mln for Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2522005445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522005445?lang=en_us&edition=fundamental","pubTime":"2025-03-25 22:57","pubTimestamp":1742914650,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2517084989","title":"ImmuneOnco Biopharmaceuticals (Shanghai)'s Cancer Drug Gets NMPA`s Nod for Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2517084989","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517084989?lang=en_us&edition=fundamental","pubTime":"2025-03-06 10:26","pubTimestamp":1741228011,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   said it received approval from China's National Medical Products Administration  for a clinical trial of IMM01 , its cancer drug, in combination with IMM2510 , according to a Thursday filing with the Hong Kong bourse.The drug is used in combination with palverafusp α for the treatment of advanced malignant tumors, with or without chemotherapy.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2517971139","title":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Gets Approval For Clinical Trial Of IMM01 (Timdarpacept)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971139?lang=en_us&edition=fundamental","pubTime":"2025-03-06 08:55","pubTimestamp":1741222512,"startTime":"0","endTime":"0","summary":"BRIEF-Immuneonco Biopharmaceuticals Shanghai Gets Approval For Clinical Trial Of IMM01 March 6  - ImmuneOnco Biopharmaceuticals Shanghai Inc 1541.HK:APPROVAL FROM NMPA CHINA FOR CLINICAL TRIAL OF IMM01 Further company coverage: 1541.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PO0IT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2517927553","title":"ImmuneOnco Biopharmaceuticals Shanghai - Approval From Nmpa China for Clinical Trial of Imm01 (Timdarpacept)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517927553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517927553?lang=en_us&edition=fundamental","pubTime":"2025-03-06 06:12","pubTimestamp":1741212725,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nFWN3PO0IT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2513713090","title":"ImmuneOnco Biopharmaceuticals Completes Disposal of Subsidiary; Shares Plunge 15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513713090","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513713090?lang=en_us&edition=fundamental","pubTime":"2025-02-24 14:54","pubTimestamp":1740380075,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   completed the sale of its subsidiary, Shanghai Zhangtou Yaoxin Technology Development, to Shanghai Zhangjiang Group, according to a Friday Hong Kong bourse filing.The biopharmaceutical firm has already received the first two payment installments of 66.2 million yuan and is set to receive the last one within 10 business days from the date on which the adjusted amount is determined.The disposal was first announced on Dec. 30, 2024, with ImmuneOnco agreeing to sell the subsidiary for up to 98.2 million yuan.Shanghai Zhangtou Yaoxin Technology Development was formed to hold an industrial property-holding company in Shanghai.Shares of the company were down nearly 15% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","SES.SI","01541"],"gpt_icon":0},{"id":"2503839521","title":"Instil Bio Inc - Plans U.S. Trial of Syn-2510/Imm2510 in 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503839521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503839521?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:00","pubTimestamp":1736856037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUAB2DZYX:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK1161","TIL","01541"],"gpt_icon":0},{"id":"2503290715","title":"Instil Bio Inc - Initial Clinical Data From 1L Advanced Nsclc Trial in China Expected 2H 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503290715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503290715?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:00","pubTimestamp":1736856037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUAB2DZYX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK4139","TIL","01541","BK4505"],"gpt_icon":0},{"id":"2503252906","title":"Instil Bio Announces Clinical Progress in China for Imm2510/Syn-2510, a Clinical-Stage Pd-L1xvegf Bispecific Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2503252906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503252906?lang=en_us&edition=fundamental","pubTime":"2025-01-14 20:00","pubTimestamp":1736856037,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250114:nTUAB2DZYX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","01541","BK4139","TIL","BK4505"],"gpt_icon":0},{"id":"2503543539","title":"Institutions along with retail investors who hold considerable shares inImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541) come under pressure; lose 11% of holdings value","url":"https://stock-news.laohu8.com/highlight/detail?id=2503543539","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503543539?lang=en_us&edition=fundamental","pubTime":"2025-01-14 09:15","pubTimestamp":1736817341,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by retail investors in ImmuneOnco Biopharmaceuticals (Shanghai) indicates that...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1541/immuneonco-biopharmaceuticals-shanghai-shares/news/institutions-along-with-retail-investors-who-hold-considerab-97","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2503565476","title":"ImmuneOnco Biopharmaceuticals' Phase Ib/II Cancer Drug Clinical Study Administers Dose on First Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2503565476","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503565476?lang=en_us&edition=fundamental","pubTime":"2025-01-14 08:47","pubTimestamp":1736815662,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   said the first patient in the Phase Ib/II clinical trial of IMM2510 in combination with chemotherapy for the first-line treatment of non-small cell lung cancer was successfully dosed, according to a Monday filing with the Hong Kong bourse.IMM2510 is a bispecific molecule developed by the group that uses a mAbTrap structure to target two proteins: VEGF, which promotes blood vessel growth, and PD-L1, which suppresses the immune system, reducing blood flow to tumors and leads to their shrinking, the filing said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","01541"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01541\",params:#limit:5,,,undefined,":[{"date":"2025-03-25","symbol":"01541","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742866200000,"name":null,"time":"Post Market","dateTimestamp":1742832000000,"actualEps":null},{"market":"HK","date":"2024-08-26","symbol":"01541","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1724601600000,"reportTimeType":"post","actualEps":null},{"date":"2024-03-25","symbol":"01541","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01541\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01541\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1697558400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01541\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01541","date":"2025-05-09","current":-7.730765,"percent":0.61165,"low":-30.003263,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"high":-2.993766,"avg":-13.662537,"sd":8.274079,"marketCap":2623061555},"quantilePoints":[{"date":"2023-08-31","current":-17.746094,"twenty":-17.746094,"median":-17.746094,"eighty":-17.746094,"marketCap":6942262047},{"date":"2023-09-08","current":-19.116691,"twenty":-19.083294,"median":-18.655615,"eighty":-17.801139,"marketCap":7390149921},{"date":"2023-09-15","current":-24.765877,"twenty":-24.765877,"median":-19.116691,"eighty":-18.557812,"marketCap":9648251285},{"date":"2023-09-22","current":-25.548224,"twenty":-25.200205,"median":-24.360534,"eighty":-18.753419,"marketCap":9909519212},{"date":"2023-09-29","current":-29.804324,"twenty":-26.447668,"median":-24.870232,"eighty":-19.083294,"marketCap":11580180660},{"date":"2023-10-06","current":-24.76052,"twenty":-26.458287,"median":-24.870232,"eighty":-19.110012,"marketCap":9615852761},{"date":"2023-10-13","current":-27.113287,"twenty":-26.458287,"median":-25.206314,"eighty":-22.322253,"marketCap":10513831229},{"date":"2023-10-20","current":-26.768577,"twenty":-26.795293,"median":-25.37532,"eighty":-23.788881,"marketCap":10364168151},{"date":"2023-10-27","current":-28.665306,"twenty":-27.124745,"median":-25.753577,"eighty":-24.00727,"marketCap":11093775656},{"date":"2023-11-03","current":-26.275244,"twenty":-27.500238,"median":-26.158488,"eighty":-24.473108,"marketCap":10195797188},{"date":"2023-11-10","current":-26.039628,"twenty":-27.37617,"median":-26.041732,"eighty":-24.763734,"marketCap":10102257765},{"date":"2023-11-17","current":-26.714897,"twenty":-27.225983,"median":-26.171076,"eighty":-24.792429,"marketCap":10457707575},{"date":"2023-11-24","current":-27.539565,"twenty":-27.37617,"median":-26.271304,"eighty":-24.846191,"marketCap":10869281039},{"date":"2023-12-01","current":-28.464343,"twenty":-27.564693,"median":-26.306056,"eighty":-24.874164,"marketCap":11280854504},{"date":"2023-12-08","current":-27.67933,"twenty":-27.70336,"median":-26.447668,"eighty":-25.070837,"marketCap":10925404694},{"date":"2023-12-15","current":-27.708906,"twenty":-27.817253,"median":-26.526325,"eighty":-25.207536,"marketCap":11000236233},{"date":"2023-12-22","current":-27.916049,"twenty":-27.937914,"median":-26.714897,"eighty":-25.244891,"marketCap":11075067772},{"date":"2023-12-29","current":-28.049426,"twenty":-27.986303,"median":-26.835368,"eighty":-25.288293,"marketCap":11187315080},{"date":"2024-01-05","current":-23.146888,"twenty":-27.970711,"median":-26.68937,"eighty":-25.200205,"marketCap":9166863527},{"date":"2024-01-12","current":-26.439512,"twenty":-27.935571,"median":-26.500765,"eighty":-25.200205,"marketCap":10476415460},{"date":"2024-01-19","current":-25.435754,"twenty":-27.916049,"median":-26.490281,"eighty":-25.212424,"marketCap":10064841995},{"date":"2024-01-26","current":-23.636611,"twenty":-27.83997,"median":-26.442842,"eighty":-24.972615,"marketCap":9316526605},{"date":"2024-02-02","current":-21.195554,"twenty":-27.817533,"median":-26.372788,"eighty":-24.783518,"marketCap":8343716598},{"date":"2024-02-09","current":-18.727145,"twenty":-27.802108,"median":-26.275244,"eighty":-24.041989,"marketCap":7408322361},{"date":"2024-02-16","current":-17.739662,"twenty":-27.801452,"median":-26.252628,"eighty":-23.794995,"marketCap":7019198358},{"date":"2024-02-23","current":-22.387155,"twenty":-27.764049,"median":-26.165159,"eighty":-23.13759,"marketCap":8811413717},{"date":"2024-03-01","current":-17.708555,"twenty":-27.735275,"median":-26.04068,"eighty":-22.460898,"marketCap":6974299434},{"date":"2024-03-08","current":-19.229551,"twenty":-27.718352,"median":-26.025076,"eighty":-21.141323,"marketCap":7576693323},{"date":"2024-03-15","current":-16.157629,"twenty":-27.69116,"median":-25.695795,"eighty":-19.998834,"marketCap":6360680815},{"date":"2024-03-22","current":-15.411367,"twenty":-27.66021,"median":-25.548224,"eighty":-19.057216,"marketCap":6061354659},{"date":"2024-03-28","current":-14.696214,"twenty":-27.629432,"median":-25.408294,"eighty":-18.737655,"marketCap":6038905197},{"date":"2024-04-05","current":-13.011166,"twenty":-27.602384,"median":-25.364375,"eighty":-18.557812,"marketCap":5342971884},{"date":"2024-04-12","current":-13.094845,"twenty":-27.539565,"median":-25.225009,"eighty":-18.239836,"marketCap":5380387654},{"date":"2024-04-19","current":-13.014894,"twenty":-27.51439,"median":-25.154554,"eighty":-17.708555,"marketCap":5342971884},{"date":"2024-04-26","current":-13.779237,"twenty":-27.443648,"median":-24.972615,"eighty":-16.602696,"marketCap":5649781194},{"date":"2024-05-03","current":-12.839078,"twenty":-27.434442,"median":-24.870232,"eighty":-16.184677,"marketCap":5260657191},{"date":"2024-05-10","current":-13.282389,"twenty":-27.357513,"median":-24.774698,"eighty":-14.702373,"marketCap":5455219193},{"date":"2024-05-17","current":-13.228926,"twenty":-27.225983,"median":-24.581805,"eighty":-14.243189,"marketCap":5425286577},{"date":"2024-05-24","current":-13.350651,"twenty":-27.145452,"median":-23.955191,"eighty":-13.966896,"marketCap":5462702347},{"date":"2024-05-31","current":-13.410156,"twenty":-27.124745,"median":-23.750163,"eighty":-13.747349,"marketCap":5492634962},{"date":"2024-06-07","current":-14.158514,"twenty":-27.039336,"median":-23.288627,"eighty":-13.645876,"marketCap":5791961118},{"date":"2024-06-14","current":-13.347574,"twenty":-26.971042,"median":-23.123643,"eighty":-13.527845,"marketCap":5455219193},{"date":"2024-06-21","current":-13.283836,"twenty":-26.926395,"median":-22.448608,"eighty":-13.452996,"marketCap":5417803423},{"date":"2024-06-28","current":-12.683619,"twenty":-26.848726,"median":-21.974147,"eighty":-13.40419,"marketCap":5170859344},{"date":"2024-07-05","current":-11.291057,"twenty":-26.759122,"median":-21.059976,"eighty":-13.359292,"marketCap":4602139648},{"date":"2024-07-12","current":-12.246119,"twenty":-26.720023,"median":-20.206581,"eighty":-13.323498,"marketCap":4998746805},{"date":"2024-07-19","current":-11.915911,"twenty":-26.704686,"median":-19.229551,"eighty":-13.282563,"marketCap":4864050035},{"date":"2024-07-26","current":-11.780484,"twenty":-26.652155,"median":-19.050696,"eighty":-13.224977,"marketCap":4826634265},{"date":"2024-08-02","current":-13.633124,"twenty":-26.594701,"median":-18.753419,"eighty":-13.20236,"marketCap":5582432809},{"date":"2024-08-09","current":-9.567144,"twenty":-26.54166,"median":-18.630761,"eighty":-13.102374,"marketCap":3943622105},{"date":"2024-08-16","current":-8.483685,"twenty":-26.496571,"median":-18.451463,"eighty":-13.086665,"marketCap":3498374448},{"date":"2024-08-23","current":-8.095604,"twenty":-26.47337,"median":-18.020488,"eighty":-13.035717,"marketCap":3352452947},{"date":"2024-08-30","current":-7.377309,"twenty":-26.446703,"median":-17.739662,"eighty":-12.990136,"marketCap":3034418906},{"date":"2024-09-06","current":-4.227864,"twenty":-26.442176,"median":-17.681919,"eighty":-12.840212,"marketCap":1739833281},{"date":"2024-09-13","current":-4.503325,"twenty":-26.43833,"median":-16.602696,"eighty":-12.741292,"marketCap":1848339013},{"date":"2024-09-20","current":-4.539912,"twenty":-26.433601,"median":-16.202037,"eighty":-12.246119,"marketCap":1874530051},{"date":"2024-09-27","current":-5.476578,"twenty":-26.311976,"median":-15.844451,"eighty":-11.915911,"marketCap":2274878785},{"date":"2024-10-04","current":-6.596451,"twenty":-26.302504,"median":-15.05764,"eighty":-11.832338,"marketCap":2727609596},{"date":"2024-10-10","current":-5.983695,"twenty":-26.285201,"median":-14.496802,"eighty":-11.807116,"marketCap":2458216056},{"date":"2024-10-18","current":-5.191078,"twenty":-26.27288,"median":-14.209972,"eighty":-11.719903,"marketCap":2121474130},{"date":"2024-10-25","current":-7.104995,"twenty":-26.248892,"median":-14.119017,"eighty":-11.287262,"marketCap":2903463713},{"date":"2024-11-01","current":-6.615271,"twenty":-26.199776,"median":-13.881638,"eighty":-9.764235,"marketCap":2705160134},{"date":"2024-11-08","current":-6.847628,"twenty":-26.169892,"median":-13.803075,"eighty":-8.441853,"marketCap":2787474827},{"date":"2024-11-15","current":-7.078843,"twenty":-26.118271,"median":-13.690467,"eighty":-8.248986,"marketCap":2851081635},{"date":"2024-11-22","current":-6.784782,"twenty":-26.059844,"median":-13.633178,"eighty":-7.853303,"marketCap":2731351173},{"date":"2024-11-29","current":-5.682581,"twenty":-26.04047,"median":-13.539989,"eighty":-7.45767,"marketCap":2286103516},{"date":"2024-12-06","current":-5.602773,"twenty":-26.037499,"median":-13.514674,"eighty":-7.358253,"marketCap":2248687746},{"date":"2024-12-13","current":-6.121403,"twenty":-26.029477,"median":-13.45004,"eighty":-7.218028,"marketCap":2451992323},{"date":"2024-12-20","current":-5.137492,"twenty":-25.962318,"median":-13.411134,"eighty":-7.087735,"marketCap":2048757705},{"date":"2024-12-27","current":-4.957491,"twenty":-25.887099,"median":-13.400213,"eighty":-7.078006,"marketCap":1975442320},{"date":"2025-01-03","current":-5.238569,"twenty":-25.753577,"median":-13.368079,"eighty":-6.925822,"marketCap":2089488475},{"date":"2025-01-10","current":-5.002231,"twenty":-25.638014,"median":-13.3526,"eighty":-6.765934,"marketCap":1987661551},{"date":"2025-01-17","current":-5.018682,"twenty":-25.5579,"median":-13.317479,"eighty":-6.665777,"marketCap":1995807705},{"date":"2025-01-24","current":-5.323319,"twenty":-25.548224,"median":-13.283546,"eighty":-6.596451,"marketCap":2130219244},{"date":"2025-01-28","current":-5.224689,"twenty":-25.503236,"median":-13.282823,"eighty":-6.532117,"marketCap":2101707706},{"date":"2025-02-07","current":-5.549725,"twenty":-25.42477,"median":-13.246663,"eighty":-6.254752,"marketCap":2219826937},{"date":"2025-02-14","current":-5.930475,"twenty":-25.395104,"median":-13.220128,"eighty":-6.076947,"marketCap":2366457707},{"date":"2025-02-21","current":-6.375256,"twenty":-25.366564,"median":-13.201126,"eighty":-6.054191,"marketCap":2557892324},{"date":"2025-02-28","current":-5.632443,"twenty":-25.318672,"median":-13.116805,"eighty":-5.974648,"marketCap":2252411553},{"date":"2025-03-07","current":-5.782376,"twenty":-25.249925,"median":-13.099044,"eighty":-5.827424,"marketCap":2321653861},{"date":"2025-03-14","current":-4.421401,"twenty":-25.219975,"median":-13.087912,"eighty":-5.725677,"marketCap":1775861550},{"date":"2025-03-21","current":-4.778207,"twenty":-25.207536,"median":-13.071662,"eighty":-5.66584,"marketCap":1918419243},{"date":"2025-03-28","current":-6.735516,"twenty":-25.163684,"median":-13.026305,"eighty":-5.651503,"marketCap":2276850015},{"date":"2025-04-03","current":-7.956153,"twenty":-25.0977,"median":-13.01303,"eighty":-5.66026,"marketCap":2684157710},{"date":"2025-04-11","current":-6.344288,"twenty":-25.036833,"median":-12.972072,"eighty":-5.68428,"marketCap":2126146167},{"date":"2025-04-17","current":-6.122985,"twenty":-24.972615,"median":-12.844749,"eighty":-5.691075,"marketCap":2056903859},{"date":"2025-04-25","current":-8.576896,"twenty":-24.895951,"median":-12.836736,"eighty":-5.703559,"marketCap":2883738480},{"date":"2025-05-02","current":-7.700417,"twenty":-24.872853,"median":-12.82514,"eighty":-5.710649,"marketCap":2594550017},{"date":"2025-05-09","current":-7.730765,"twenty":-24.846191,"median":-12.683619,"eighty":-5.725677,"marketCap":2623061555}],"updateTime":1746884354642}}}